Physician profile
Tonya Evette Carter
NPI 1760859458
$4,093.22
in general payments reported to CMS, 2019-2025
17 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $411 · 2023: $678 · 2024: $535 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788 · Travel and Lodging: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,788.26 |
| Travel and Lodging | $468.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,481.08 | 2023-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $534.68 | 2021-2023 | Xarelto |
| Abbott Laboratories | $464.21 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lexicon Pharmaceuticals, INC. | $329.92 | 2023-2024 | Inpefa |
| Medtronic, INC. | $199.61 | 2021-2024 | Linq II, Tyrx |
| Alnylam Pharmaceuticals INC. | $157.12 | 2025 | Amvuttra, Onpattro |
| Abiomed | $145.71 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.84 | 2025 | |
| Edwards Lifesciences Corporation | $121.12 | 2021-2022 | |
| Pfizer INC. | $117.40 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.72 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $97.26 | 2023 | |
| Philips North America LLC | $77.95 | 2023-2025 | (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided |
| Amgen INC. | $75.17 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $20.33 | 2024 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.21 | 2022 | |
| Bridgebio Pharma, INC. | $16.89 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.